CYTH Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 29.78%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Cyclo Therapeutics Insider Trading History Chart

Cyclo Therapeutics Share Price & Price History

^$0.72

+0.30 (1.20%)

As of 03/26/2025 01:00 AM ET

Cyclo Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/1/2023	Rafael Holdings, Inc.	Major Shareholder	Buy	4,000,000	$1.25	$5,000,000.00	6,514,970
4/20/2023	Jeffrey Tate	COO	Buy	29,941	$0.71	$21,258.11	62,101
4/20/2023	Markus Sieger	Director	Buy	59,881	$0.71	$42,515.51	161,051
4/20/2023	N. Scott Fine	CEO	Buy	299,402	$0.71	$212,575.42	444,402

SEC Filings (Institutional Ownership Changes) for Cyclo Therapeutics (NASDAQ:CYTH)

68.55% of Cyclo Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Cyclo Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/14/2025	Two Sigma Securities LLC	42,541	$25K	0.0%	N/A	0.148%
2/7/2025	EPIQ Capital Group LLC	689,447	$0.41M	0.1%	-6.8%	2.396%
8/10/2024	EPIQ Capital Group LLC	817,270	$1.04M	0.4%	-4.3%	2.856%
2/15/2024	Founders Fund V Management LLC	480,708	$0.76M	80.8%	N/A	2.115%
2/15/2024	Founders Fund VI Management LLC	110,023	$0.18M	1.4%	N/A	0.484%

Data available starting January 2016

Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.

Today's Range

Now: $0.72

$0.72

50 Day Range

MA: $0.72

$0.72

52 Week Range

Now: $0.72

$0.55

$1.45

Volume

N/A

Average Volume

585,177 shs

Market Capitalization

$23.72 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Cyclo Therapeutics?: Cyclo Therapeutics' top insider investors include:
Rafael Holdings, Inc (Major Shareholder)
N Scott Fine (CEO)
Markus Sieger (Director)
Francis Patrick Ostronic (Director)
Jeffrey Tate (COO)
Sharon Hemond Hrynkow (Insider)
Joshua M Fine (CFO)
Learn More about top insider investors at Cyclo Therapeutics.